Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M34.7Revenue $M0Net Margin (%)0Z-Score-5.3
Enterprise Value $M10.2EPS $-1.2Operating Margin %0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book1.510-y EBITDA Growth Rate %0Quick Ratio12.8Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-38.1Current Ratio12.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-35.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-44.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M22.7ROI % (ttm)-70.8Gross Margin Increase y-yN

Gurus Latest Trades with BIOD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIODDavid Swensen 2010-12-31 Sold Out $6.44 - $19.08
($10.24)
$ 1.56-85%Sold Out0
BIODDavid Swensen 2009-12-31 Buy 11.73%$14.16 - $21.04
($16.88)
$ 1.56-91%New holding, 903400 sh.903,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIOD is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BIOD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LIEBERMAN IRADirector 2013-12-20Buy10,800$2.29-31 view
Pereira Brian JGDirector 2013-12-20Sell4,734$2.26-30.09 view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-12-07Sell12,256$2.8-43.57 view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-11-02Sell3,500$2.81-43.77 view
Krasner Alan SethChief Medical Officer 2012-11-02Sell3,500$2.81-43.77 view
DESOUZA ERROL BCEO 2012-09-20Buy10,000$3.34-52.69 view
Bavier Paul SGeneral Counsel/Corp. Sec. 2012-03-13Sell2,096$2.36-33.05 view
Pereira Brian JGDirector 2011-12-16Sell3,750$2.6-39.23 view
Steiner SolomonDirector 2011-09-26Sell32,695$4.36-63.76 view
Steiner SolomonDirector 2011-09-21Sell79,129$4.72-66.53 view

Press Releases about BIOD :

    Quarterly/Annual Reports about BIOD:

    News about BIOD:

    Articles On GuruFocus.com
    cooldecency99 note on BIOD May 01 2010 
    Biodel Reports Third Quarter Fiscal Year 2009 Financial Results Aug 07 2009 
    Biodel to Report Third Quarter Fiscal Year 2009 Results on August 7, 2009 Aug 03 2009 
    Biodel Reports First Quarter Fiscal Year 2009 Financial Results and Clinical Update Feb 05 2009 
    Biodel to Report First Quarter Fiscal Year 2009 Results and Top Line Results of Bioequivalence Study Jan 30 2009 
    Biodel Inc. Reports Fourth Quarter and Fiscal Year 2008 Financial Results Dec 10 2008 


    More From Other Websites
    Nasdaq stocks posting largest volume increases Nov 21 2014
    Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent... Nov 18 2014
    Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% Nov 18 2014
    Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% Nov 07 2014
    Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% Oct 30 2014
    BIODEL INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 27 2014
    Biodel Announces Data Presentations at the 50th Annual Meeting of the EASD Sep 15 2014
    BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Aug 27 2014
    Biodel Appoints Gary G. Gemignani as Chief Financial Officer Aug 25 2014
    BIODEL INC Financials Aug 22 2014
    Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update Aug 14 2014
    BIODEL INC Files SEC form 10-Q, Quarterly Report Aug 13 2014
    [video] Stocks Close Higher, But Off Day's Highs Aug 11 2014
    BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 11 2014
    Biodel Reports Third Quarter Fiscal Year 2014 Financial Results Aug 11 2014
    Biodel's insulin drug found effective in trial Aug 11 2014
    Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized... Aug 11 2014
    Biodel to Present at the Wedbush PacGrow Life Sciences Management Access Conference Aug 06 2014
    Biodel to Report Third Quarter Fiscal Year 2014 Financial Results on August 11, 2014 Aug 05 2014
    Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital Jul 28 2014
    Biodel to Present at the JMP Securities Healthcare Conference Jun 11 2014
    Biodel to Present Data on Ultra-Rapid-Acting Insulin and Glucagon Product Candidates at 2014... Jun 10 2014
    BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers May 23 2014
    Biodel to Present at the 26th Annual ROTH Conference Mar 04 2014
    Biodel Announces Plans to Advance BIOD-531 Based on Positive Clinical Trial Results Feb 12 2014
    Biodel Reports First Quarter Fiscal Year 2014 Financial Results Feb 06 2014
    Biodel to Report First Quarter Fiscal Year 2014 Financial Results on February 6, 2014 Feb 05 2014
    Biodel Reports Fourth Quarter Fiscal Year 2013 Financial Results Dec 18 2013
    Biodel Announces Commercial Supply Agreement With BD for Liquid Glucagon Rescue Device Dec 17 2013
    Biodel to Report Fourth Quarter Fiscal Year 2013 Financial Results on December 18, 2013 Dec 12 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK